Evidence map›Paper›PMID 40900331›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Mapping the global research landscape of tirzepatide: a bibliometric analysis of trends, collaborations, and emerging themes in obesity and diabetes managements.

Manal Mohamed Elhassan Taha, Siddig Ibrahim Abdelwahab, Omar Oraibi, Mohammed A Madkhali, Abdulhameed Albarraq Alhazmi, Mohammed Jeraiby, Saleh M Abdullah, Abdullah Farasani, Jobran M Moshi, Nizar A Khamjan and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Manal Mohamed Elhassan TahaHealth Research Centre, Jazan University, Jazan, Saudi Arabia.
Siddig Ibrahim AbdelwahabHealth Research Centre, Jazan University, Jazan, Saudi Arabia. sadiqa@jazanu.edu.sa.
Omar OraibiFaculty of Medicine, Jazan University, Jazan, Saudi Arabia.
Mohammed A MadkhaliFaculty of Medicine, Jazan University, Jazan, Saudi Arabia.
Abdulhameed Albarraq AlhazmiUniversity Hospital, Jazan University, Jazan, Saudi Arabia.
Mohammed JeraibyDepartment of Basic Medical Science, Faculty of Medicine, Jazan University, Jazan, Saudi Arabia.
Saleh M AbdullahDepartment of Medical Laboratory Technology, Faculty of Nursing and Health Sciences, Jazan University, Jazan, Saudi Arabia.
Abdullah FarasaniDepartment of Medical Laboratory Technology, Faculty of Nursing and Health Sciences, Jazan University, Jazan, Saudi Arabia.
Jobran M MoshiDepartment of Medical Laboratory Technology, Faculty of Nursing and Health Sciences, Jazan University, Jazan, Saudi Arabia.
Nizar A KhamjanDepartment of Medical Laboratory Technology, Faculty of Nursing and Health Sciences, Jazan University, Jazan, Saudi Arabia.
Saeed AlshahraniDepartment of Pharmacology and Toxicology, College of Pharmacy, Jazan, Saudi Arabia.
Hussam M ShubailyFaculty of Medicine, Jazan University, Jazan, Saudi Arabia.
Khaled A SahliSecurity Forces Hospitals Program, General Directorate of Medical Services, Ministry of Interior, Riyadh, Kingdom of Saudi Arabia.
Marwa QadriDepartment of Pharmacology and Toxicology, College of Pharmacy, Jazan, Saudi Arabia.
Amani KhardaliDepartment of Clinical Pharmacy, College of Pharmacy, Jazan University, Jazan, Saudi Arabia.

Funding

Jazan University 296
6 · The paper itself

Abstract

Tirzepatide, a dual GIP/GLP-1 receptor agonist, shows promise in managing obesity and type 2 diabetes. This bibliometric analysis maps its research landscape, identifying trends, collaborations, and emerging themes to guide future investigations. A structured search of the Scopus database was performed using the keywords "tirzepatide" in titles or abstracts, limited to English-language original articles. A total of 446 documents were retrieved. Bibliometric analysis was conducted using VOSviewer (v1.6.19), Biblioshiny (Rstudio plugin), and CiteSpace (v6.2.R6) to visualize co-authorship, keyword co-occurrence, citation patterns, and thematic evolution. Tirzepatide publications peaked in 2024 (n = 163), with the USA leading (n = 243, 10,076 citations). Key authors included Urva, S. and Haupt, A. Three thematic clusters emerged: pharmacological mechanisms, clinical outcomes, and study design. Emerging topics included weight reduction, pharmacovigilance, and cost-effectiveness. Co-citation analysis identified four author clusters, with Frias J.P. (TLS = 13,605) most influential. Journals like Diabetes, Obesity and Metabolism dominated. Thematic evolution showed shifts toward real-world evidence and metabolic dysfunction-associated steatotic liver disease, reflecting broadening research scope. Tirzepatide research is growing globally with diverse collaborations, informing future therapeutic strategies and highlighting gaps in long-term safety, accessibility, and cost-effectiveness.

Indexed as

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsObesityAnimalsBibliometricsBiomedical ResearchHumansTirzepatideGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsTirzepatideBibliometric analysisGLP-1 receptor agonistsObesityTirzepatideType 2 diabetes mellitus

Identifiers

PMID40900331

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.